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ABSTRACT
MODULATION OF INTERLEUKIN-17 BY TUMOR NECROSIS FACTORALPHA DURING THE IMMUNE RESPONSE TO BORRELIA BURGDORFERI
by
Velinka Medić
The University of Wisconsin-Milwaukee, 2013
Under the Supervision of Professor Dean Nardelli
Arthritis is one of the main complications of late-stage Lyme borreliosis. Cytokines
play an important role in the persistent inflammation that is elicited by the causative
agent of disease, Borrelia burgdorferi. Tumor necrosis factor alpha (TNF-α) is a
pro-inflammatory cytokine that is induced by B. burgdorferi and that has been
implicated in development of arthritis. However, in a mouse model of Lyme
arthritis, treatment with anti-TNF-α antibody increased the severity of disease. By
contrast, injection of recombinant TNF-α ameliorated arthritis in this model. These
findings suggested that other factors might be involved during the development of
Lyme arthritis. One possible factor may be interleukin-17 (IL-17), a proinflammatory cytokine mainly produced by T helper 17 cells. IL-17 has been
implicated in the development of Lyme arthritis. Treatment with anti-IL-17
antibodies reduces the inflammatory outcome in animal models of disease.
However, it is not known how TNF-α affects the response of IL-17 to B. burgdorferi.
The hypothesis of this thesis is that TNF-α will regulate the immune response to
B. burgdorferi infection by decreasing IL-17 production. Modulation of IL-17 during
the immune response to B. burgdorferi was analyzed in wild-type and interleukin10 (IL-10)-deficient mice treated with anti-TNF-α antibodies. We found that anti-
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TNF-α antibody treatment increased paw inflammation in both wild-type and IL-10
deficient mice. In addition, cell cultures from B. burgdorferi-infected, wild-type mice
treated with anti-TNF-α antibodies typically produced a greater amount of IL-17
than untreated controls, reasoning that TNF-α decreases IL-17 levels following
infection. Additional treatment of anti-TNF-α antibody-treated mice with anti-IL-17
antibodies lessened the severity of paw swelling. Our results indicate that TNF-α
can play a protective role during the immune response to B. burgdorferi infection
by restraining the production of IL-17.
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CHAPTER 1: INTRODUCTION
I. Lyme Borreliosis
Zoonotic pathogens have become a threat to human health, despite increased
awareness and surveillance. The most common tick-borne disease in the United
States is Lyme borreliosis (Centers for Disease Control and Prevention [CDC]), a
multi-symptom disease caused by excessive inflammation elicited by Borrelia
burgdorferi, the pathogenic spirochete. The number of cases of Lyme borreliosis
has continued to increase annually, with 30,000 reported cases in 2012 (CDC).
However, in 2013 it was reported that the actual incidence of disease is 10 times
higher than reported cases, reaching 300,000 per year (CDC). Lyme borreliosis is
endemic to the East Coast and Great Lakes regions and northern California. This
geographic pattern, which is expanding, is a result of the combined presence of
suitable tick vectors and prevalence of infected ticks and animal reservoirs.

B. burgdorferi sensu lato is a complex of 19 genospecies (Rudenko et al., 2011).
Some of these species are pathogens that cause the development of Lyme
borreliosis. These pathogenic strains have different geographic ranges and cause
different disease manifestations. For example, B. burgdorferi sensu stricto is
responsible for causing Lyme borreliosis in the United States. This species is well
known for inducing the development of Lyme arthritis in later-stage infection. By
contrast, B. garinii and B. afzelii are responsible for causing Lyme borreliosis in
Europe, and, in later stages of disease, typically cause more severe effects of the
skin and neurological system than B. burgdorferi. These pathogens are deficient
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in the genes necessary for synthesis of amino acids and fatty acids (AgueroRosenfeld et al., 2005), and, therefore, depend on host cells and tissues and
immune evasion for survival.

The progression of Lyme borreliosis is often divided into three stages: early
localized disease, early disseminated disease, and late disease (Steere et al.,
1989). The main clinical manifestation of early disease that is caused by B.
burgdorferi is a bull’s eye-shaped rash called erythema migrans (EM). EM is
present in about 70% of cases of infection (Bacon et al., 2008) and, in endemic
areas, it is considered to be diagnostic (Aguero-Rosenfeld et al., 2005; Wormser
et al., 2006). EM develops at the site of the tick bite approximately 7 to 14 days
after infection and usually is accompanied by non-specific, flu-like symptoms
(O’Connor, 2010). In early disseminated disease, in which B. burgdorferi
organisms migrate from the skin throughout the body, multiple EM lesions can be
present, as well as cranial nerve palsy, meningitis, and, rarely, carditis. During this
stage, fever, fatigue, and headache are also common. The most commonly
manifested complication of late disease in the United States is arthritis, but
neurological symptoms such as mood and memory disorders, fatigue, and nerve
pain may also be observed. By contrast, encephalomyelitis and acrodermatitis
chronica atrophicans (a skin rash that can lead to skin atrophy and
polyneuropathy) are common late symptoms of Lyme borreliosis in Europe (Stanek
et al., 1996), which is a result of infection with pathogenic species other than B.
burgdorferi, such as B. afzelii and B. garinii.
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II. Transmission and Dissemination of B. burgdorferi
Complex interactions between the microbes, vectors, and animal reservoirs lead
to transmission of B. burgdorferi. The transmission of B. burgdorferi to humans
depends on the infected deer tick Ixodes scapularis, which is found in the eastern
and midwestern parts of United States, and I. pacificus, which is found on the
Pacific coast. In order to understand the transmission of B. burgdorferi, it is
important to describe the life cycle of I. scapularis. The life cycle of the tick ranges
from two to four years, and it is divided into four stages: egg, larva, nymph, and
adult. When I. scapularis ticks hatch, they are free of bacteria. At the first feeding
on an infected animal reservoir, B. burgdorferi are transmitted into the larvae. After
molting to the nymph stage, infected I. scapularis feed on another animal reservoir
and transmit the bacteria to them, which sustains the presence of the bacteria in
the environment. During the nymph stage, I. scapularis may also feed on humans,
transmitting the bacteria to them. It has been suggested that humans are
accidental or “dead-end” hosts (Radolf et al., 2012). Ticks feed on white-footed
mice, which are considered the main animal reservoir (Mather et al., 1989), and
deer, which are less competent reservoirs for B. burgdorferi (Telford et al., 1988).
Other animal reservoirs include squirrels, hares, and various other small
mammals, as well as birds and lizards (Halperin, 2011). In addition, seasons that
correspond to the tick life cycle are also important in the transmission of Lyme
borreliosis. Summer months are when larvae hatch and feed on infected animal
reservoirs, as well as when nymphs also feed. In these months, there is an
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increase in the number of reported Lyme borreliosis cases (Bacon et al., 2008).
Overall, the prevalence of Lyme borreliosis is dependent on a combination of the
feeding habits of these ticks, the proportion of ticks infected with B. burgdorferi,
and the presence of animal reservoirs.

The effects of host and tick factors on B. burgdorferi are especially important in
transmission of the spirochete. There is a change in expression of various outersurface proteins (Osp) of B. burgdorferi, mainly OspA and OspC, during the tick
feedings. In the infected, but unfed, tick, bacteria are contained in the midgut.
OspA levels are upregulated during colonization of tick midgut, and it has been
established that OspA plays a role in adhesion to the epithelial cells of ticks by
binding to a protein named “tick receptor for OspA” (TROSPA) (Pal et al., 2004).
During feeding, there is a downregulation of OspA, causing detachment of B.
burgdorferi from TROSPA and migration to the salivary gland. Concomitantly,
there is an upregulation of OspC, which can bind tick salivary protein 15 (Salp15)
(Ramamoorthi et al., 2005). It has been demonstrated that Salp15 is needed for B.
burgdorferi infection. It inhibits CD4+ T cell activation, and its attachment to the
bacteria allows dissemination into the mammalian host (Samuels, 2010).

After infection with B. burgdorferi, the spirochetes disseminate from the skin into
the blood and various organs. To enter specific organs, they have to evade host
defenses and induce the breakdown of extracellular matrix (ECM) components of
tissues. Other Osp proteins that are produced by the bacteria ensure successful
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infection and survival in the hosts. When B. burgdorferi enters the mammalian
host, it disseminates and survives by evading the immune response. OspEFrelated proteins (Erps) bind to complement factor H and complement factor H-like
1 protein (FHL-1) to inhibit the activity of the alternative complement pathway
(Antonara et al., 2011). In addition, B. burgdorferi does not produce secreted
proteases. Instead, it has to rely on inducing host factors that result in tissue
destruction and dissemination into tissues. For example, B. burgdorferi induces
production of plasminogen and matrix metalloproteinase-9 (MMP-9), which cause
ECM degradation (Heilpern et al., 2009). Similarly, adhesion molecules, including
outer-membrane surface proteins (OMPs), integrin binding protein p66 (Coburn et
al., 1999), the fibronectin binding protein Bbk32 (Probert and Johnson, 1998), and
decorin-binding proteins A and B (Hagman et al., 1998), have been shown to aid
in dissemination within the host, particularly to sites of abundant connective tissue.
Collectively, these findings demonstrate that different bacterial, tick, and host
factors for are responsible for successful transmission, establishment of infection,
and dissemination.

III. Diagnosis and Treatment of Lyme Borreliosis
The diagnosis of Lyme borreliosis is dependent on a combination of laboratory
testing and observing clinical manifestations. The CDC requires confirmed cases
of Lyme borreliosis to meet the following criteria: physician-confirmed EM, or
positive serological testing with manifestations of cardiac, neurological, or arthritic
symptoms (CDC). Aside from EM, the clinical manifestations are not specific.
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However, diagnosis based on EM alone is often difficult. EM does not develop in
every infected patient, and EM may occasionally be confused with rash, eczema,
and insect bites (Puius and Kalish, 2007). In addition, EM lesions can be located
on a part of the body that is difficult to observe, and the rash can be obscured by
certain skin tones and the presence of hair. As a result, diagnosis of Lyme
borreliosis only on the basis of observing clinical symptoms can be difficult.
However, observing EM in an endemic area is often sufficient for a positive
diagnosis.

Additionally, serological testing is frequently used to diagnose Lyme borreliosis. A
two-step process is used for laboratory diagnosis: a screening enzyme-linked
immunosorbent assay (ELISA), followed by a confirmatory Western blot. One
major disadvantage of this approach is an inability to distinguish between current
and past infection, since patients can be seropositive for years (Marques, 2010).
Similarly, detection of B. burgdorferi-specific antibodies in the early stage of
disease can be challenging, since the sensitivity and specificity of serological
testing are inadequate at that stage (Shapiro and Gerber, 2000). Furthermore,
cross-reactive antibodies from other spirochetal infections such as syphilis,
relapsing fever, or leptospirosis, or from autoimmune diseases such as systemic
lupus erythematosus, can yield false positives. These issues demonstrate the
complexity of diagnosing Lyme borreliosis and the need for better diagnostic
markers.
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In 2006, the Infectious Diseases Society of America updated the stage-dependent
guidelines for treatment of Lyme disease (Wormser et al., 2006). For adults at an
early stage of Lyme disease with no neurological complications, doxycycline,
amoxicillin, or cefuroxime axetil are recommended for 10-21 days. During the late
stage of Lyme disease, patients with Lyme arthritis can be treated with the same
antibiotics, but administered for 28 days. If arthritis is not resolved by the end of
the first treatment, a second dose of antibiotics is administered for another 4 weeks
(Shapiro and Gerber, 2000; Wormser et al., 2006).

However, some patients can still present with arthritic symptoms even after a
second dose of antibiotics. At this point, non-steroidal anti-inflammatory agents
and corticosteroids are used to counter the high levels of pro-inflammatory
cytokines found in patients (Shin et al., 2007). In addition, disease-modifying antirheumatic drugs may be used to combat synovial destruction.

There is an ongoing debate in the field of Lyme arthritis research as to whether
patients treated with several doses of antibiotics continue to be infected with B.
burgdorferi. This is particularly due to the inability to isolate live bacteria from
synovial fluid of patients that suffer from late stage Lyme arthritis (Carlson et al.,
1999; Shin et al., 2007). Different hypotheses have been proposed to explain the
cause of continued synovitis in these patients in the absence of bacteria. Steere
and Glickstein (2004) proposed the following hypotheses for this persistent
arthritis: (1) B. burgdorferi might reside in a location that is not easily accessible to
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antibiotics; (2) bacterial antigens, rather than live microbes, may have a continued
presence in the synovial fluid and tissues; (3) the response to B. burgdorferi may
cause autoimmunity due to T-cell epitope mimicry, and (4) infection may cause
bystander activation of inflammatory cells. Recently, the “amber hypothesis” was
proposed, postulating that antigens can become trapped in connective tissue (as
if they were in amber), and then get released into the joint, eliciting a strong
immune response (Wormser et al., 2012). This has been proposed as a possible
explanation for why active infection is not observed in patients with antibioticresistant Lyme arthritis (Wormser et al., 2012). This theory questions the persistent
use of antibiotics in treatment of late-stage Lyme disease because antigens, rather
than live microbes, would elicit the inflammatory immune response. Therefore,
non-recommended treatments for Lyme arthritis need to be approached with
caution, and other targets, such as the immune response, need to be considered
for therapy.

IV. Lyme Arthritis
Various cells and cytokines have been implicated in the development of Lyme
arthritis. Strong innate and adaptive immune responses are activated during the
inflammatory process against B. burgdorferi; however, the exact mechanisms of
Lyme arthritis are not fully understood. It has been demonstrated that during the
innate response, neutrophils (Brown et al., 2003) and macrophages (Du Chateau
et al., 1996) are activated in the synovial tissue. Similarly, there is an influx of
complement proteins, as well as pro-inflammatory chemokines and cytokines, into
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the synovial fluid of patients with Lyme arthritis (Shin et al., 2007). These innate
factors lead to an inflammatory T cell-mediated response that often results in
arthritis.

i. Animal Models of Lyme Arthritis
Animal models are used to study the immunopathogenic mechanisms of Lyme
arthritis. The selection of an animal model depends on the purpose of the study
because no animal model is able to combine all of the inflammatory events
presented in humans with Lyme arthritis (Nardelli et al., 2008b).

Infection of experimental mice with B. burgdorferi is used to study various features
of Lyme arthritis. C3H/HeJ mice are the most commonly used mice for this disease
model. Induction of Lyme arthritis is achieved by feeding of infected ticks or by
injection of B. burgdorferi into the paws or between shoulder blades of the mice.
Distinctive features of this model include synovitis that develops and resolves in 36 weeks (Barthold et al., 1992) and that does not lead to cartilage or bone erosion
(Barthold et al., 1992; Nardelli et al., 2010). In addition, this model exhibits a strong
response by innate immune cells (Barthold et al., 1996, Nardelli et al., 2010).
Contrary to this animal model, in humans, Lyme arthritis develops months to years
after infection, and both innate and adaptive immune responses are important in
this progression. Therefore, use of C3H mice in the study of Lyme arthritis may be
best used to investigate the innate immune response following infection.
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Using the infection model of disease, wild-type C57BL/6 mice are resistant to
development of severe Lyme arthritis (Barthold et al., 1992, Ma et al., 1998). When
C57BL/6 mice are injected with high doses of bacteria (up 2 x 105), they show
minimal paw swelling, while C3H mice show severe paw swelling (Ma et al., 1998).
However, infected C57BL/6 mice have a similar number of spirochetes as infected
C3H mice, even though they develop mild arthritis (Ma et al., 1998). It has been
proposed that differences in susceptibility between these two strains are linked to
interleukin-10 (IL-10) production and its role in the immune response (Brown et al.,
1999, Ganapamo et al., 2000). C57BL/6 macrophages stimulated with B.
burgdorferi produce more IL-10 than stimulated cells from C3H mice (Brown et al.,
1999). Furthermore, recombinant IL-10 down-regulates pro-inflammatory cytokine
production by bone-marrow derived macrophages, while treatment with anti-IL-10
antibody increases levels of pro-inflammatory cytokines produced by these
macrophages (Gautam et al., 2012). These studies demonstrate the basic
differences between C3H and C57BL/6 mice and the involvement of the antiinflammatory cytokine IL-10 in regulating the immune response in these mice
following infection with B. burgdorferi.

Involvement of IL-10 in regulating Lyme arthritis has led researchers to utilize IL10-deficient mice on both the C57BL/6 and C3H backgrounds to study the disease.
C57BL/6 IL-10-deficient mice infected with B. burgdorferi have increased levels of
paw swelling (Brown et al., 1999; Hansen et al., 2013), immune cell infiltrates
(Sonderegger et al., 2012) and arthritis (Brown et al., 1999; Hansen et al., 2013)
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while maintaining lower numbers of spirochetes than infected wild-type mice
(Brown et al., 1999; Sonderegger et al., 2012). Sonderegger et al. (2012) noted
the importance of adaptive immunity in this model, as there is direct involvement
of T cells following infection (Sonderegger et al., 2012). Therefore, infected IL-10deficient mice may be a feasible model to study the involvement of the adaptive
immune response in development of later stage Lyme arthritis, which is observed
in humans (Sonderegger et al., 2012; Hansen et al., 2013).

ii. T Cell Mediation of Lyme Arthritis
While innate immunity is involved in causing joint inflammation during early
infection, T cells– more specifically, T helper type 1 (Th1) cells– are involved in the
development of later-stage Lyme arthritis. Th1 cells produce an important proinflammatory cytokine, interferon-gamma (IFN-γ), which has been associated with
the development of Lyme arthritis (Yssel et al., 1991). However, several groups
were able to elicit Lyme arthritis in IFN-γ-deficient mice (Brown and Reiner, 1999;
Christopherson et al., 2003; Burchill et al., 2003). These studies demonstrate that
Th1 cells are not solely responsible for development of Lyme arthritis. Recently, a
subset of T helper cells which produce interleukin-17 (IL-17), T helper type 17
(Th17 cells), has been proposed to also play an important role in the
immunopathogenesis of Lyme arthritis, particularly in later disease (Nardelli et al.,
2008b).
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What factors support the hypothesis that IL-17-producing cells are involved in
Lyme arthritis development? B. burgdorferi induces the production of IL-17 from
cells of mice (Knauer et al., 2006) and humans with Lyme arthritis (Infante-Duarte
et al., 2000). In addition, treatment with anti-IL-17 antibody in Borrelia-vaccinated
and -infected mice prevented development of arthritis (Burchill et al., 2003;
Nardelli, et al. 2004, 2005, 2008a). Also, Th17 cells have been found in the
synovial fluid of Lyme arthritis patients (Codolo et al., 2008, 2013; Shen et al.,
2010). Furthermore, infected, arthritic mice produce increased amounts of IL-17,
which can be reduced by antibodies to various Th17-cell-related cytokines
(Amlong et al. 2006; Kotloski et al. 2008; Nardelli et al., 2008b). This evidence
shows that B. burgdorferi is able to elicit an IL-17 response that may contribute to
the development of Lyme arthritis.

Other support for a potential role of IL-17-producing cells in the development of
Lyme arthritis comes from experimental models of rheumatoid arthritis (RA)
because of its similarities in pathology and clinical symptoms to Lyme arthritis. For
example, in collagen-induced arthritis, it has been shown that IL-17 causes bone
resorption and cartilage destruction (Lubberts et al., 2001, 2002). Furthermore,
increased levels of IL-17 mRNA were noted in the synovia and lymph nodes in
mice using a model of adjuvant arthritis (Bush et al., 2001). Similarly, Lubberts
(2008) reported that IL-17-induced expression of NF-κB, which was necessary for
osteoclastogenesis and bone resorption. These studies indicate the involvement
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of IL-17 in development in several models of arthritis, supporting the concept that
it may also be involved in the development of Lyme arthritis.

iii. TNF-α and Lyme Arthritis
Tumor necrosis factor-alpha (TNF-α) is a pro-inflammatory cytokine, produced by
activated T cells and macrophages, that has been shown to play a role in
rheumatoid arthritis pathogenesis (Katz et al., 2001). In addition, TNF-α plays a
role in the immune response to B. burgdorferi and affects the pathogenesis of
Lyme arthritis. Peripheral blood mononuclear cells (PBMCs) (Defosse and
Johnson, 1992) and macrophages (Ma and Weis, 1993) produce TNF-α when
incubated with B. burgdorferi. Additionally, synovial fluid from patients with Lyme
arthritis was found to have higher levels of TNF-α than the synovial fluid of nonarthritic patients (Defosse and Johnson, 1992). Currently, there are five FDAapproved TNF-α inhibitors used as therapies for rheumatoid arthritis (Dinarello
2005). Therefore, it is possible that TNF-α may be a viable target for the inhibition
or prevention of Lyme arthritis.

The role of these TNF-α inhibitors is to neutralize the cytokine, preventing binding
to its receptors. However, about 30% to 50% of rheumatoid arthritis patients
receiving TNF-α inhibitor therapy do not see improvements (Rubbert-Roth and
Finckh, 2009). Surprisingly, however, Christopherson et al. (2003) demonstrated
that neutralization of TNF-α actually increased the severity of arthritis in a mouse
model of Lyme arthritis, while treatment with recombinant TNF-α ameliorated

14
disease. Another protective property of TNF-α in Lyme arthritis was demonstrated
by Yrjänainen et al. (2007). Administration of antibodies to TNF-α did not
ameliorate arthritic swelling; in addition, when neutralization of TNF-α was coupled
with ceftriaxone therapy, the number of spirochetes actually increased (Yrjänainen
et al., 2007). Both of these studies provide caution about the use of anti-TNF-α
antibody for Lyme arthritis and highlight the need for further studies to elucidate
the mechanism of TNF-α in its pathogenesis. While blocking TNF-α may be
therapeutic for rheumatoid arthritis, it may not be for Lyme arthritis. This
demonstrates that TNF-α may influence additional factors involved in the
inflammatory response to B. burgdorferi.

The pro-inflammatory cytokine IL-17 may be one such factor. The interactions
between IL-17 and TNF-α are complex and cause various downstream
inflammatory effects. Jovanovic et al. (1998) found that IL-17 can induce the
production of TNF-α in human macrophages. In addition, in human-TNF-α
transgenic mice, blocking IL-17 production led to a decreased number of
osteoclasts and played a protective role in TNF-α-mediated arthritis (Zwerina et
al., 2012). This study also demonstrated that IL-17 played a role not only in the
inflammation of the joints, but also in joint destruction. Furthermore, IL-17 is able
to induce the production of TNF-α and interleukin-1-beta (IL-1β) in the serum of
rheumatoid arthritis patients (Chen et al., 2011). Also, IL-17 was able to stimulate
macrophages to release TNF-α along with IL-1β in vitro (Jovanovic et al., 1998).
Additionally, IL-17 and TNF-α were shown by Katz et al. (2001) to act
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synergistically in promoting inflammation. Addition of TNF-α and IL-17 to
fibroblasts led to secretion of both interleukin-6 and interleukin-8. The additive
effect of these two cytokines was also shown in cultures of rheumatoid arthritis
synoviocytes, in which their actions induced hypoxia inducible factor 1 alpha, which
is found in high levels in patients (Hot et al., 2012).

While many studies show that IL-17 influences the production of TNF-α, others
show that TNF-α influences the activity of IL-17. Iwamoto et al. (2007) showed that
TNF-α assists in differentiation of mature dendritic cells that stimulate a Th17
response. Also, use of the TNF-α inhibitor pentoxifylline to treat an animal model
of rheumatoid arthritis reduces IL-17 levels in joint tissues. However, this treatment
did not affect IL-17 levels in the periodontal-associated aspects of the experimental
disease (Queiroz-Junior et al., 2013). Similar to this, Chen et al. (2011) showed
that rheumatoid arthritis patients who responded to anti-TNF-α therapy produced
fewer Th17 cells and IL-17 than untreated patients. However, patients who did not
respond to treatment produced more Th17 cells and IL-17 (Chen et al., 2011).
However, Koenders et al. (2006) showed that IL-17 acts independently of TNF-α
in an in vivo rheumatoid arthritis model.

These findings show the complex relationship between TNF-α and IL-17. In some,
but not all, contexts, blocking TNF-α reduces IL-17 production. The role of TNF-α
in inducing IL-17-mediated Lyme arthritis is not fully known.
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V. Borreliacidal Antibody Response
B. burgdorferi infection stimulates production of antibodies with highly specific
killing activity against the spirochete. Borreliacidal antibodies specific to the outer
surface proteins (Callister et al., 1994) cause the killing of the bacteria by activation
of complement. Schmitz et al. (1990) demonstrated that injection of immune sera
into infected mice protected against swelling, joint destruction and infection of
tissues. Similarly, Lovrich et al. (1993) demonstrated that serum from infected
hamsters was able to kill B. burgdorferi in vitro. Production of these borreliacidal
antibodies can be used to determine protection against B. burgdorferi. It was
shown that the presence of borreliacidal antibodies correlates with elimination of
B. burgdorferi from tissues (Schmitz et al., 1991; Creson et al., 1996), while the
total antibody response is sustained for a longer amount of time (Padilla et al.,
1996). Collectively, these studies show that borreliacidal antibody production is
important for protection against B. burgdorferi.

Different outer-surface proteins, including OspA, OspB and OspC, were identified
as immunogens that produce borreliacidal antibodies. A recombinant OspA
vaccine was made available on the market in 1998 but was removed after 4 years.
Both of the clinical trials for the recombinant OspA vaccine (Sigal et al., 1998;
Steere et al., 1998) required two boosters, underlining the importance of
maintaining a strong humoral immune response in the protection against B.
burgdorferi, which is the basis for developing effective Lyme borreliosis vaccines.
Prior to this, Padilla et al. (1996) demonstrated that borreliacidal antibody titers
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waned quickly after vaccination. By determining the immune mechanisms that
influence microbial clearance through borreliacidal antibodies, additional factors
that induce protection can be identified.

VI. HYPOTHESIS AND SPECIFIC AIMS
Arthritis is one of the major complications of late stage Lyme borreliosis. Cytokines
play an important role in mediation of inflammation elicited by B. burgdorferi
infection. Specifically, IL-17 has been implicated in development of Lyme arthritis
(Infante-Duarte et al., 2000; Burchill et al., 2003; Nardelli et al., 2004, 2005, 2008a;
Knauer et al., 2006; Hansen et al., 2013). However, the role of the proinflammatory cytokine TNF-α remains to be further elucidated. Incubation of
peripheral blood mononuclear cells (Defosse and Johnson, 1992) and
macrophages (Ma and Weis, 1993) with B. burgdorferi induce production of TNFα. However, a protective role for TNF-α in Lyme arthritis was demonstrated
(Christopherson et al., 2003; Yrjänainen et al., 2007). Studies of rheumatoid
arthritis and psoriasis indicate that TNF-α can regulate IL-17 (Moran et al., 2009;
Chen et al., 2011), while others indicate an independent relationship between TNFα and IL-17 in arthritis development (Koenders et al., 2006; Iwamoto et al., 2007).
However, the effect of TNF-α on IL-17 production during B. burgdorferi infection
has not been explored. The objective of this research is to elucidate the role of
TNF-α and IL-17 in the inflammatory process of Lyme arthritis. The hypothesis of
this thesis is that TNF-α will regulate the immune response to B. burgdorferi
infection by decreasing IL-17 production.
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The following specific aims of this proposal are:
1. Determine the effect of TNF-α on IL-17 in the immune response to B.
burgdorferi infection. The working hypothesis of this aim is that TNF-α will
decrease IL-17 production following B. burgdorferi infection.

2. Determine the effects of TNF-α on the borreliacidal antibody response
following infection with B. burgdorferi. The working hypothesis of this
aim is that anti-TNF-α treatment of B. burgdorferi-infected mice will inhibit
borreliacidal antibody production, which will be reversed by also blocking
IL-17.
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CHAPTER 2: MATERIALS AND METHODS
I. Mice
Female and male, 6 to-12 week old wild-type and IL-10-deficient C57BL/6 mice
were obtained from Dr. J.-A. Lyons (University of Wisconsin-Milwaukee). These
mice were housed and cared for in the animal facility at the University of
Wisconsin-Milwaukee. Food and water were provided ad libitum. The protocols
and guidelines were reviewed and approved by the University of WisconsinMilwaukee Institutional Animal Care and Use Committee.

II. Infection of Mice with B. burgdorferi
Borrelia burgdorferi strain 297 was provided by S. M. Callister (Gundersen
Lutheran Medical Center, La Crosse, WI). B. burgdorferi organisms were grown in
Barbour-Stoenner-Kelly (BSK) medium for 2-4 days at 34ºC. Mice were
anesthetized with isoflurane in a nose-to-mouth cup and infected subcutaneously
with 106 spirochetes (0.05 ml) into the hind paws.

III. Administration of Anti-Cytokine Antibodies
Anti-IL-17 and isotype control antibodies were purchased from Affymetrix
eBioscience (San Diego, CA), while anti-TNF-α and isotype control antibodies
were purchased from R & D Systems (Minneapolis, MN). Antibodies were
reconstituted in phosphate buffered saline (PBS) to achieve a concentration of 2.5
µg/ml. One day after infection, two groups of 5 infected mice were anesthetized
with isoflurane and then injected in the hind paw with 2.5 µg of TNF-α antibody.
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One of these two anti-TNF-α antibody-treated groups was simultaneously injected
with 2.5 µg of anti-IL-17 antibody, while the other was simultaneously injected with
an isotype control antibody. A third group of infected mice was injected with antiIL-17 antibody and an isotype control antibody. An additional group of infected
mice was injected with isotype control antibodies. These antibody treatments were
administered for four consecutive days following the initial treatment.

IV. Assessment of Inflammation
Mice were anesthetized with isoflurane in a nose-to-mouth cup. Using a Vernier
caliper, hind paws were measured for thickness and width, and the average of
these two measurements was calculated as the “mean paw value”. Swelling of the
hind paws was measured prior to injections on the day of infection and at the time
of sacrifice, 8 days post infection. The measurements of hind paw swelling on day
8 after infection were compared to the measurements of paw thickness prior to
infection. Since the different groups of mice did not have equal values of initial paw
thickness, the overall increase in swelling from the day of infection to day 8 after
infection was also determined.

V. Cell Culture
Spleens were collected and used for in vitro culture studies to assess production
of IL-17. Single-cell suspensions were obtained by passing the tissue through a
100-µm nylon cell strainer into Roswell Park Memorial Institute 1640 (RPMI)
medium. 2 x106 spleen cells in RPMI medium were incubated at 37°C in 5% CO2,
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with or without 105 B. burgdorferi 297 organisms in BSK medium. Supernatants
were collected after 18 and 24 hours of incubation.

VI. In Vitro Administration of Anti-Cytokine Antibodies
In another study, wild-type and IL-10-deficient C57BL/6 mice were infected
subcutaneously with 106 spirochetes (0.05 ml) in the hind paws. Non-infected
control mice received an injection of BSK medium. Ten days after infection, mice
were sacrificed, and single-cell suspensions were prepared from spleens, as
described previously. 2 x 106 spleen cells in RPMI medium were incubated at 37°C
in 5% CO2, with or without 105 B. burgdorferi 297 organisms in BSK medium in a
total volume of 1 ml. Additionally, cells were incubated with isotype-control
antibodies or with anti-TNF-α antibodies, anti-IL-17 antibodies, or both anti-TNF-α
and anti-IL-17 antibodies. Antibodies were added to wells in concentrations of 2.5
µg/ml, 5 µg/ml, or 10 µg/ml. Cells from non-infected mice were incubated with or
without spirochetes and with or without 2.5 µg/ml anti-TNF-α antibodies, anti-IL-17
antibodies, or both anti-TNF-α and anti-IL-17 antibodies. Supernatants were
collected after 24 hours of incubation.

VII. ELISA
Supernatants were analyzed for IL-17 production using the Mouse IL-17A
(homodimer) ELISA Ready-SET-Go! Kit (Affymetrix eBioscience) according to the
manufacturer’s instructions. Samples were analyzed in duplicates and plates were
read at 450nm.
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VIII. Borreliacidal Antibody Assay
Serum was collected from mice for the assessment of borreliacidal antibodies.
Equal amounts of serum were pooled within a group. Each serum sample was heat
inactivated in a 56°C water bath for 30 minutes, diluted 1:20 in BSK medium, and
then serially diluted to 1:40,960. Subsequently, 105 B. burgdorferi strain 297
organisms in 50 µL of BSK medium were added to the diluted wild-type serum,
and 104 B. burgdorferi strain 297 organisms were added to the diluted IL-10deficient serum. Then, 10 µL of guinea pig complement were added, and the
samples were incubated for 16 hours at 32°C. After incubation, samples were
examined for motile B. burgdorferi (at least 30 fields per sample) using darkfield
microscopy. The borreliacidal antibody titer was the inverse of the first dilution that
showed no live organisms. Controls included heat-inactivated serum from naïve
mice incubated with B. burgdorferi and guinea pig complement, B. burgdorferi
incubated with guinea pig complement, and B. burgdorferi incubated in BSK
medium.

IX. Statistics
The results of some studies were expressed as mean ± standard error of the mean
(SEM) and analyzed using a two-tailed Student's t-Test to determine the level of
significance. Other data were analyzed by one-way analysis of variance (ANOVA)
followed by the Tukey-Kramer post-hoc test. All P-values were calculated with the
alpha level set at 0.05 prior to initiation of experiments.
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CHAPTER 3: RESULTS
I. Paw inflammation after antibody treatment of B. burgdorferi-infected mice.
B. burgdorferi-infected wild-type and IL-10-deficient mice were treated for four
consecutive days after infection with anti-TNF-α antibodies, anti-IL-17 antibodies,
or both anti-TNF-α and anti-IL-17 antibodies. Paws were measured prior to
infection and at the time of sacrifice (day 8 after infection). The hind paws of
infected but untreated wild-type mice were larger on day 8 after infection compare
to baseline levels. This increase was not significant, however (P = 0.07; data not
shown). By contrast, the hind paws of infected wild-type mice treated with antiTNF-α antibodies were significantly larger on day 8 after infection compared to
baseline levels (P = 0.006; data not shown). In addition, no significant differences
in hind paw swelling were observed between days 0 and 8 of infection in wild-type
mice treated with anti-IL-17 antibodies, alone or also with anti-TNF-α antibodies
(data not shown).

We then measured the overall change in hind paw swelling in infected wild-type
mice by subtracting measurements at day 8 from baseline values. The change in
paw swelling of infected, anti-TNF-α antibody-treated mice was slightly, but not
significantly, greater than the overall change of swelling in infected but untreated
mice (Fig. 1). Additionally, the overall change in swelling in anti-IL-17 antibodytreated mice was slightly, but insignificantly, less than the control group. However,
the overall change in paw swelling in anti-TNF-α antibody-treated mice was
significantly greater than the degree of swelling in anti-IL-17 antibody-treated mice
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(P = 0.045). Administration of antibodies against both IL-17 and TNF-α did not
significantly change the magnitude of paw swelling compared to infected mice
treated with anti-IL-17 antibodies (Fig. 1).

Figure 1. Overall change in paw swelling following treatment of B. burgdorferi-infected
wild-type mice. Mice were infected with B. burgdorferi and then injected with antibodies to
TNF-α, IL-17, both cytokines, or neither cytokine for four days. Treatment with TNF-α
antibodies slightly, but not significantly, increased paw swelling in mice that were otherwise
not treated or treated with anti-IL-17 antibodies. Values indicate means ± SEM. Groups
consisted of 4-5 mice each.

In contrast to infected wild-type mice, all antibody-treated groups of B. burgdorferiinfected IL-10-deficient mice exhibited larger paws at day 8 after infection
compared to baseline levels. At day 8 after infection, significantly larger paws were
exhibited by infected IL-10-deficient mice that were untreated (P = 0.0008) or
treated with anti-TNF-α (P = 1 x 10-6) or anti-IL-17 (P = 6 x 10-5) antibodies,
compared to their baseline paw thickness (data not shown). Infected IL-10deficient mice treated with both antibodies exhibited larger paws by day 8 after
infection. However, this increase was not significant (P = 0.06; data not shown).

Compared to the overall change in paw swelling of infected but untreated IL-10deficient mice, a significantly greater overall change in swelling was observed in
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mice treated with anti-TNF-α (P = 0.0001) or anti-IL-17 (P = 0.01) antibodies (Fig.
2). However, the overall change in paw swelling in infected mice treated with antiIL-17 antibodies was not different than the change in paw swelling by mice treated
with antibodies to both IL-17 and TNF-α.

Figure 2. Overall change in paw swelling following treatment of B. burgdorferi-infected
IL-10-deficient mice. Mice were infected with B. burgdorferi and then injected with antibodies
to TNF-α, IL-17, both cytokines, or neither cytokine for four days. Treatment with anti-TNF-α
or anti-IL-17 antibodies resulted in a significantly greater overall change in paw swelling
compared to untreated controls. However, additional treatment with anti-TNF-α did not result
in swelling changes in anti-IL-17 antibody-treated mice. Values indicate means ± SEM.
Groups consisted of 4-5 mice each. *, P ≥ 0.05.

II. Effects of anti-cytokine antibodies on IL-17 production in B. burgdorferiinfected, wild-type mice.
To assess the involvement of TNF-α on production of IL-17 during B. burgdorferi
infection, C57BL/6 wild-type mice were treated with anti-TNF-α and/or anti-IL-17
antibodies for four consecutive days after infection. Eight days after infection,
spleen cells were obtained and incubated in the absence (Fig. 3) or presence (Fig.
4) of B. burgdorferi for 18 hours. When incubated for 18 hours, unstimulated spleen
cells from infected, anti-TNF-α antibody-treated wild-type mice produced
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significantly greater amounts of IL-17 than unstimulated spleen cells from
untreated, infected mice (56 pg/ml vs. 30 pg/ml; P = 0.05; Fig. 3). Surprisingly,
unstimulated spleen cells from infected, anti-IL-17 antibody-treated wild-type mice
produced significantly more IL-17 than unstimulated spleen cells from untreated,
infected mice (68 pg/ml vs. 30 pg/ml; P = 0.005; Fig. 3). Unstimulated spleen cells
from infected mice injected with antibodies against both IL-17 and TNF-α produced
less IL-17 than unstimulated cells from infected, anti-IL-17 antibody treated mice
(45 pg/ml vs. 68 pg/ml). However, this decrease in IL-17 production due to
administration of anti-TNF-α antibodies did not achieve statistical significance (Fig.
3).

Figure 3. Production of IL-17 by unstimulated spleen cells from B. burgdorferi-infected,
antibody (Ab)-treated wild-type mice after 18 hours of incubation. Eight days after
infection, spleen cells from Ab-treated, wild-type mice were incubated for 18 hours in the
absence of B. burgdorferi. Unstimulated cells from anti-TNF-α and anti-IL-17 Ab-treated mice
produced significantly more IL-17 than unstimulated cells from untreated, infected mice.
Additional treatment with anti-TNF-α Ab did not affect IL-17 production by cells of anti-IL-17
Ab-treated mice. Values indicate means ± SEM. Groups consisted of 4-5 mice each. *, P ≥
0.05.

Additionally, cells from these groups of antibody-treated, B. burgdorferi-infected
wild-type mice were stimulated in vitro with B. burgdorferi for 18 hours. Stimulation
of spleen cells from infected, anti-TNF-α antibody-treated wild-type mice induced
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slightly, but insignificantly, more IL-17 than stimulated spleen cells from infected
but untreated mice (67 pg/ml vs. 45 pg/ml; P = 0.08; Fig. 4). B. burgdorferistimulated spleen cells harvested from infected, anti-IL-17 antibody-treated mice
produced similar amounts of IL-17 than cells from infected but untreated mice (42
pg/ml vs. 45 pg/ml; Fig. 4). In addition, stimulated cells from infected mice treated
with anti-IL-17 antibody produced similar amounts of IL-17 than cells from infected
mice treated with both anti-IL-17 and anti-TNF-α antibodies (42 pg/ml vs. 48 pg/ml;
Fig. 4).

Figure 4. Production of IL-17 by B. burgdorferi-stimulated spleen cells from B.
burgdorferi-infected, Ab-treated wild-type mice after 18 hours of incubation. Eight days
after infection, spleen cells from Ab-treated, wild-type mice were incubated for 18 hours in the
presence of B. burgdorferi. Stimulated cells from anti-TNF-α Ab-treated mice produced
slightly, but not significantly, more IL-17 than stimulated cells from untreated, infected mice.
Anti-TNF-α Ab treatment did not affect IL-17 production by cells from mice treated with antiIL-17 Abs. Values indicate means ± SEM. Groups consisted of 4-5 mice each.

The effects of in vitro stimulation with B. burgdorferi, for 18 hours, on IL-17
production by these cells were then compared. Incubation of cells from infected,
untreated wild-type mice with B. burgdorferi slightly, but insignificantly, increased
production of IL-17 (Fig. 5). Similar findings were observed among stimulated cells
obtained from infected mice that were treated with anti-TNF-α antibodies (Fig. 5).
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By contrast, stimulation of cells from infected, anti-IL-17 antibody-treated mice
significantly decreased IL-17 production (Fig. 5).

Figure 5. Effect of in vitro stimulation with B. burgdorferi for 18 hours on
production of IL-17 from infected mice treated with anti-cytokine Abs. Stimulation
with B. burgdorferi (darker bars) caused a slight, but insignificant, increase in IL-17
production by spleen cells obtained from infected mice that were untreated or treated
with anti-TNF-α Abs. By contrast, stimulation caused a significant decrease in IL-17
production by cells obtained from infected mice treated with anti-IL-17 Abs. Values
indicate means ± SEM. Groups consisted of 4-5 mice each. *, P ≥ 0.05.

Spleen cells were also incubated with or without B. burgdorferi for 24 hours.
Unstimulated cells from infected, anti-TNF-α antibody-treated mice produced
slightly, but insignificantly, less IL-17 than spleen cells from infected but untreated
wild-type mice (28 pg/ml vs. 44 pg/ml; P = 0.13; Fig. 6). However, unstimulated
cells from infected, anti-IL-17 antibody-treated mice produced significantly less IL17 than unstimulated cells from infected but untreated mice (21 pg/ml vs. 44 pg/ml;
P = 0.02; Fig. 6). However, addition of anti-TNF-α antibody to infected, anti-IL-17
antibody-treated mice did not significantly affect IL-17 production by spleen cells
incubated in the absence of B. burgdorferi for 24 hours (32 pg/ml vs. 21 pg/ml; Fig.
6).
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Figure 6. Production of IL-17 by unstimulated spleen cells from B. burgdorferiinfected, Ab-treated wild-type mice after 24 hours of incubation. Eight days after
infection, spleen cells from Ab-treated, wild-type mice were incubated for 24 hours in the
absence of B. burgdorferi. Unstimulated cells from anti-TNF-α Ab-treated mice produced
a similar amount of IL-17 than unstimulated cells from untreated, infected mice. By
contrast, cells from anti-IL-17 Ab-treated mice produced significantly less IL-17 than cells
from control mice. The level of IL-17 produced by cells from anti-IL-17 Ab-treated mice
was comparable to that of cells from anti-IL-17 and -TNFα Ab-treated mice. Values
indicate means ± SEM. Groups consisted of 4-5 mice each. *, P ≥ 0.05.

After 24 hours of incubation, B. burgdorferi-stimulated spleen cells from infected,
anti-TNF-α antibody-treated mice produced similar amounts of IL-17 as stimulated
cells from infected but untreated mice (18 pg/ml vs. 26 pg/ml; P = 0.36; Fig. 7).
Also, stimulated cells from infected, anti-IL-17 antibody-treated mice produced
less, although statistically similar, amounts of IL-17 as stimulated cells from
infected but untreated mice (9 pg/ml vs. 26 pg/ml; P = 0.13; Fig 7). Interestingly,
stimulated cells harvested from infected mice treated with both anti-IL-17 and antiTNF-α antibodies did not produce detectable levels of IL-17. However, this
difference was not statistically different from stimulated spleen cells from infected,
anti-IL-17 antibody-treated mice (Fig. 7).
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Figure 7. Production of IL-17 by B. burgdorferi-stimulated spleen cells from B.
burgdorferi-infected, Ab-treated wild-type mice after 24 hours of incubation. Eight
days after infection, spleen cells from Ab-treated, wild-type mice were incubated for 24
hours in the presence of B. burgdorferi. Stimulated cells from anti-TNF-α and anti-IL-17
Ab-treated mice produced a similar amount of IL-17 as unstimulated cells from untreated,
infected mice. By contrast, cells from dual-Ab-treated mice produced undetectable
amounts of IL-17. While this was significantly less compared to cells of untreated or antiTNF-α Ab-treated mice, it was not significantly different compared to cells of IL-17 Abtreated mice. Values indicate means ± SEM. Groups consisted of 4-5 mice each. *, P ≥
0.05.

The effects of in vitro stimulation with B. burgdorferi, for 24 hours, on IL-17
production by these cells were then compared. Incubation of cells from infected,
untreated wild-type mice with B. burgdorferi decreased production of IL-17 by cells
from all groups of treated mice (Fig. 8). However, a statistically significant decrease
in IL-17 production was observed following stimulation of cells only from infected
mice treated with anti-TNF-α and anti-IL-17 antibodies. (Fig. 8).
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Figure 8. Effect of in vitro stimulation with B. burgdorferi for 24 hours on
production of IL-17 from infected mice treated with anti-cytokine Abs. Stimulation
with B. burgdorferi (darker bars) for 24 hours caused a decrease in IL-17 production by
spleen cells obtained from infected mice treated with anti-cytokine Abs. A statistically
significant decrease in IL-17 production was observed following stimulation of cells from
dual-Ab-treated mice. Values indicate means ± SEM. Groups consisted of 4-5 mice each.
*, P ≥ 0.05.

III. Effects of anti-cytokine antibodies on IL-17 production in B. burgdorferiinfected, IL-10-deficient mice.
The effect of TNF-α on IL-17 production following B. burgdorferi infection in the
absence of IL-10 was then determined. B. burgdorferi-infected, IL-10-deficient
mice were treated for four consecutive days with anti-TNF-α antibody and/or antiIL-17 antibodies. Spleen cells were collected eight days after infection and
incubated with or without B. burgdorferi. Eighteen hours after incubation,
unstimulated spleen cells obtained from all groups of mice produced low or
undetectable levels of IL-17 (data not shown). By contrast, stimulated spleen cells
from anti-TNF-α antibody-treated mice produced significantly greater amounts of
IL-17 than stimulated cells from non-treated mice after 18 hours of stimulation with
B. burgdorferi (27 pg/ml vs. 0.39 pg/ml; P = 0.02; Fig. 9). Stimulated cells from
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infected, IL-10-deficient mice treated with anti-IL-17 antibodies produced an
undetectable amount of IL-17 after 18 hours of incubation. Additional treatment of
these mice with anti-TNF-α antibodies did not lead to a change in IL-17 production
following stimulation for 18 hours (Fig. 9).

Figure 9. Production of IL-17 by B. burgdorferi-stimulated spleen cells from B.
burgdorferi-infected, Ab-treated IL-10-deficient mice after 18 hours of incubation. Eight
days after infection, spleen cells from Ab-treated, IL-10-deficient mice were incubated for 18
hours in the presence of B. burgdorferi. Stimulated cells from anti-TNF-α Ab-treated mice
produced significantly, more IL-17 than stimulated cells from untreated, infected mice. Values
indicate means ± SEM. Groups consisted of 4-5 mice each. *, P ≥ 0.05.

Cells from these mice were also incubated in the presence or absence of B.
burgdorferi for 24 hours (Fig. 10). Unstimulated cells from infected, IL-10-deficient
mice treated with anti-TNF-α antibody produced IL-17 after 24 hours of incubation.
However, these levels were equal to IL-17 production by unstimulated cells from
untreated mice (27 pg/ml vs. 25 pg/ml; P = 0.82; Fig. 10). Similarly, unstimulated
cells collected from infected, anti-IL-17 antibody-treated mice
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Figure 10. Production of IL-17 by unstimulated spleen cells from B. burgdorferiinfected, Ab-treated IL-10-deficient mice after 24 hours of incubation. Eight days after
infection, spleen cells from Ab-treated, IL-10-deficient mice were incubated for 24 hours
in the absence of B. burgdorferi. No differences in IL-17 production were observed among
cells from any of the Ab-treated mice. Values indicate means ± SEM. Groups consisted of
4-5 mice each.

produced a similar amount of IL-17 as unstimulated cells from infected, untreated
mice (24 pg/ml vs. 25 pg/ml; P = 0.92; Fig. 10). Additionally, treatment of infected
mice with antibodies against both IL-17 and TNF-α did not affect the production of
IL-17 from stimulated spleen cells compared to infected, anti-IL-17 antibodytreated mice (23 pg/ml vs. 24 pg/ml; P = 0.87; Fig. 10). Overall, unstimulated cells
from infected, IL-10 deficient mice produced consistent levels of IL-17 between all
four different treatment groups after incubation for 24 hours.

Additionally, production of IL-17 was not significantly different between spleen cells
from the untreated and single-antibody-treated groups of infected, IL-10-deficient
mice after incubation with B. burgdorferi for 24 hours (Fig. 11).
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Figure 11. Production of IL-17 by B. burgdorferi-stimulated spleen cells from B.
burgdorferi-infected, Ab-treated IL-10-deficient mice after 24 hours of incubation.
Eight days after infection, spleen cells from Ab-treated, IL-10-deficient mice were
incubated for 24 hours in the presence of B. burgdorferi. Cells from anti-TNF-α Ab-treated
mice produced a similar amount of IL-17 as cells from untreated mice. Although the
amount of IL-17 produced by cells of dual-Ab-treated mice was significantly greater than
controls, it was similar to that of cells from anti-IL-17 Ab-treated mice. Values indicate
means ± SEM. Groups consisted of 4-5 mice each. *, P ≥ 0.05.

Stimulated spleen cells that were obtained from B. burgdorferi-infected mice that
were treated with anti-TNF-α antibodies produced similar amounts of IL-17 as did
cells from infected, untreated mice (25 pg/ml vs. 23 pg/ml; Fig. 11). Likewise,
stimulated cells from infected, IL-10-deficient mice treated with anti-IL-17 antibody
produced similar levels of IL-17 as spleen cells from infected, untreated mice (Fig.
11). Injection of anti-TNF-α and anti-IL-17 antibodies to infected IL-10-deficient
mice did not significantly alter the production of IL-17 by spleen cells compared to
that of infected mice treated with only anti-IL-17 antibody (Fig. 11).

IV. Production of IL-17 by wild-type cells following in vitro antibody
treatment.
Spleen cells were harvested from B. burgdorferi-infected wild-type mice 10 days
after infection. The cells were incubated with the spirochete and with antibodies to
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TNF-α and/or IL-17 for 24 hours to provide information about the effect of TNF-α
on IL-17 production without the variables associated with treatment in vivo. We
first treated stimulated spleen cells obtained from wild-type, B. burgdorferi-infected
mice with 2.5 µg of antibodies for 24 hours. Cells that were incubated with 2.5 µg
of anti-TNF-α antibody produced significantly more IL-17 than non-treated cells (32
pg/ml vs. 17 pg/ml; P = 0.037; Fig. 12). In contrast, cells incubated with 2.5 µg of
anti-IL-17 antibody produced a similar amount of IL-17 as untreated cells (Fig. 12).
Furthermore, treatment with both anti-IL-17 and anti-TNF-α antibodies did not
affect production of IL-17 compared to cells treated with anti-IL-17 antibody alone
(Fig. 12).

Figure 12. Effect of 2.5 µg in vitro anti-cytokine Abs on production of IL-17 in wild-type
cells. Wild-type mice were infected with B. burgdorferi. Eight days later, spleen cells were
incubated with 2.5 µg of anti-TNF-α Ab, anti-IL-17 Ab, or both anti-TNF-α and antil-IL-17 Ab
for 24 hours. Cells treated with anti-TNF-α Ab produced significantly more IL-17 than
untreated cells. However, anti-TNF-α Ab treatment did not affect IL-17 production by cells
treated with anti-IL-17 Ab. Values indicate means ± SEM. Groups consisted of 4-5 mice each.
*, P ≥ 0.05.

We then treated stimulated spleen cells from wild-type B. burgdorferi-infected mice
with a greater (5 µg) concentration of antibodies and measured the production of
IL-17 (Fig. 13). Treatment with anti-TNF-α antibody did not affect IL-17 production
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compared to non-treated cells (Fig. 13). Similarly, treatment of cells with anti-IL-17
antibody did not change IL-17 levels in comparison to non-treated cells (Fig. 13).
However, cells that were treated with both anti-IL-17 and anti-TNF-α antibodies
produced significantly greater levels of IL-17 than cells treated with just anti-17
antibody (35 pg/ml vs 25 pg/ml; P = 0.005; Fig. 13).

Figure 13. Effect of 5 µg in vitro anti-cytokine Abs on production of IL-17 in
wild-type cells cells. Wild-type mice were infected with B. burgdorferi. Eight days
later, spleen cells were incubated with 5 µg of anti-TNF-α Ab, anti-IL-17 Ab, or both
Abs for 24 hours. Anti-TNF-α Ab treatment of IL-17 Ab-treated cells caused a
significant increase in IL-17 production compared to cells treated with anti-IL-17 Ab
alone. Values indicate means ± SEM. Groups consisted of 4-5 mice each. *, P ≥ 0.05.

In addition, a concentration of 10 µg of each antibody was administered to the
spleen cells harvested from infected wild-type mice. However, cells from all four
groups produced similar amounts of IL-17 (Fig. 14). Spleen cells incubated with
anti-TNF-α antibody did not affect production of IL-17 compared to untreated cells.
Similarly, anti-IL-17 antibody-treated cells produced similar amounts of IL-17 as
non-treated cells. Additionally, anti-IL-17 antibody-treated cells produced similar
amounts of IL-17 as cells treated with antibodies against both IL-17 and TNF-α
(Fig. 14).
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Figure 14. Effect of 10 µg in vitro anti-cytokine Abs on production of IL-17 in wild-type
cells. Wild-type mice were infected with B. burgdorferi. Eight days later, spleen cells were
incubated with 10 µg of anti-TNF-α Ab, anti-IL-17 Ab, or both anti-TNF-α and antil-IL-17 Ab
for 24 hours. Anti-TNF-α Ab treatment had no effect on IL-17 production at this concentration.
Values indicate means ± SEM. Groups consisted of 4-5 mice each. *, P ≥ 0.05.

V. Production of IL-17 by IL-10-deficient cells following in vitro antibody
treatment.
Spleen cells were harvested from B. burgdorferi-infected, IL-10-deficient mice 10
days after infection. The cells were incubated with the spirochete and with
antibodies to TNF-α and/or IL-17 for 24 hours to provide information about the
effect of TNF-α on IL-17 production without the variables associated with treatment
in vivo. Spleen cells harvested from infected IL-10-deficient mice and incubated
with 2.5 µg anti-TNF-α antibody produced a similar amount of IL-17 as untreated
cells (84 pg/ml vs. 88 pg/ml; Fig. 15). By contrast, spleen cells treated with 2.5 µg
of anti-IL-17 antibody produced a significantly smaller amount of IL-17 than nontreated cells (43 pg/ml vs. 84 pg/ml; P = 0.0004; Fig. 15). Contrary to that which
was observed in wild-type cells, treatment with both antibodies led to an even
greater decrease in IL-17 production (29 pg/ml). However, this decrease was not
statistically different than IL-17 production from anti-IL-17 antibody-treated cells (P
= 0.12; Fig. 15).
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Figure 15. Effect of 2.5 µg in vitro anti-cytokine Abs on production of IL-17 in IL-10deficient cells. IL-10-deficient mice were infected with B. burgdorferi. Eight days later, spleen
cells were incubated with 2.5 µg of anti-TNF-α Ab, anti-IL-17 Ab, or both anti-TNF-α and antilIL-17 Ab for 24 hours. Cells treated with anti-IL-17 Ab produced significantly less IL-17 than
untreated cells, but cells treated with anti-TNF-α Ab alone had no effect. Anti-TNF-α Ab
treatment did not affect IL-17 production by cells also treated with anti-IL-17 Ab. Values
indicate means ± SEM. Groups consisted of 4-5 mice each. *, P ≥ 0.05.

We then treated stimulated spleen cells from IL-10-deficient, B. burgdorferiinfected mice with a greater (5 µg) concentration of antibodies and measured the
production of IL-17 (Fig. 16). Spleen cells that were harvested from infected mice
and treated with anti-TNF-α antibody produced similar amounts of IL-17 as
untreated cells from infected mice (Fig. 16). As expected, cells treated with antiIL-17 antibody produced significantly less IL-17 than non-treated cells (30 pg/ml
vs. 73 pg/ml; P = 0.009; Fig. 16). However, addition of anti-TNF-α antibodies to
cells treated with anti-IL-17 antibodies did not affect IL-17 production (28 pg/ml vs.
30 pg/ml; P = 0.90; Fig. 16).
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Figure 16. Effect of 5 µg in vitro anti-cytokine Abs on production of IL-17 in IL-10deficient cells. IL-10-deficient mice were infected with B. burgdorferi. Eight days later, spleen
cells were incubated with 5 µg of anti-TNF-α Ab, anti-IL-17 Ab, or both anti-TNF-α and antilIL-17 Ab for 24 hours. Cells treated with anti-IL-17 Ab, with or without anti-TNF-α Ab, produced
significantly less IL-17 than untreated cells. Cells treated with anti-TNF-α Ab alone had no
effect on IL-17 production. Values indicate means ± SEM. Groups consisted of 4-5 mice each.
*, P ≥ 0.05.

In addition, 10 µg of antibodies were administered to spleen cells collected from B.
burgdorferi-infected, IL-10-deficient mice (Fig. 17). Spleen cells incubated with
anti-TNF-α antibody produced similar amounts of IL-17 as non-treated cells (P =
0.70; Fig. 17). As expected, treatment of cells with anti-IL-17 antibody significantly
decreased IL-17 production compared to untreated cells (24 pg/ml vs. 69 pg/ml; P
= 0.002; Fig. 17). However, the production of IL-17 by anti-IL-17 antibody-treated
cells was similar to the production of IL-17 by cells treated with both anti-TNF-α
and anti-IL-17 antibodies (P = 0.50).
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Figure 17. Effect of 10 µg in vitro anti-cytokine Abs on production of IL-17 in IL-10deficient cells. IL-10-deficient mice were infected with B. burgdorferi. Eight days later, spleen
cells were incubated with 10 µg of anti-TNF-α Ab, anti-IL-17 Ab, or both anti-TNF-α and antilIL-17 Ab for 24 hours. Cells treated with anti-IL-17 Ab produced significantly less IL-17 than
untreated cells. Cells treated with anti-TNF-α Ab alone, or in addition to anti-IL-17 Ab, had no
effect on IL-17 production. Values indicate means ± SEM. Groups consisted of 4-5 mice each.
*, P ≥ 0.05.

Overall, spleen cells from B. burgdorferi-infected, IL-10-deficient mice produced
an increased amount of IL-17 than spleen cells from infected wild-type mice.
Treatment of spleen cells from infected, IL-10 deficient mice with 2.5 µg or 10 µg
of anti-TNF-α antibody induced a significantly greater amount of IL-17 than
treatment of corresponding wild-type cells (P = 5 x 10-6 and 0.009; Fig. 18 and data
not shown, respectively). However, these increases were also observed among
untreated cells (Fig. 18 and data not shown). In contrast, no differences were
observed in production of IL-17 by wild-type and IL-10-deficient cells after
incubation with anti-IL-17 antibodies or with both anti-IL-17 and anti-TNF-α
antibodies (Fig. 18 and data not shown). No changes in IL-17 production were
observed between wild-type and IL-10-deficient cells treated with 5 µg of antibody
(data not shown).
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Figure 18. Effect of IL-10 deficiency on IL-17 production. Untreated or anti-TNF-α Abtreated cells from IL-10-deficient mice (open bars) produce significantly more IL-17 than wildtype counterparts (closed bars) when incubated with 2.5 µg Ab. No difference in IL-17
production was observed when cultures contained anti-IL-17 antibody. Values indicate
means ± SEM. Groups consisted of 4-5 mice each. *, P ≥ 0.05.

Interestingly, within all four treated groups, there were no significant differences in
production of IL-17 with an increased amount of their respective antibodies (data
not shown). Surprisingly, treatment of spleen cells with increased concentrations
of anti-IL-17 antibodies did not significantly reduce IL-17 levels in either IL-10
deficient or wild-type mice, although trends toward less production were observed
(data not shown). Spleen cells from infected wild-type or IL-10 deficient mice, when
incubated with anti-TNF-α antibodies, exhibited no dose-response in IL-17
production, even when anti-IL-17 antibodies were also added (data not shown).

VI. Borreliacidal antibody titers.
The purpose of this experiment was to evaluate the killing activity of serum
antibodies directed against B. burgdorferi in wild-type and IL-10-deficient mice
treated with anti-TNF-α and/or anti-IL-17 antibodies. A one-fold greater difference
was noted in borreliacidal antibody titers of infected, anti-TNF-α antibody-treated

42
mice than infected, untreated mice (Fig. 19A). Sera from infected mice treated with
both anti-TNF-α and anti-IL-17 antibodies possessed a one-fold greater titer of
borreliacidal antibodies than infected mice that received antibodies to IL-17 alone
(Fig. 19A).

Figure 19. Borreliacidal antibody production. Borreliacidal antibody titers from serum of
wild-type (A) and IL-10-deficient (B) mice. Mice were infected with B. burgdorferi and were
untreated or treated with anti-TNF-α Ab, anti-IL-17 Ab, or both anti-TNF-α and anti-IL-17 Abs
for 4 days following infection. Sera were collected on day 8 after infection. Groups consisted
of 4-5 mice each.

By contrast, serum from infected, anti-TNF-α antibody-treated, IL-10-deficient mice
had a three-fold less borreliacidal antibody titer than serum from infected,
untreated IL-10-deficient mice (Fig. 19B). In addition, the sera from infected IL-10deficient mice treated with both anti-IL-17 and anti-TNF-α antibodies exhibited a
two-fold higher borreliacidal antibody titer than the sera from mice treated with antiIL-17 antibody alone (Fig. 19B).
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CHAPTER 4: DISCUSSION
This thesis describes the effect of TNF-α on IL-17 production during the immune
response to B. burgdorferi infection in wild-type and IL-10 deficient C57BL/6 mice.
The central hypothesis was that TNF-α will regulate the immune response to B.
burgdorferi infection by decreasing IL-17 production. To analyze the effect of TNFα on IL-17 in a mouse infection model of Lyme arthritis, B. burgdorferi-infected
mice were treated with anti-TNF-α antibodies to quantify in vitro IL-17 production,
paw swelling, and borreliacidal antibody production. Additionally, isolated spleen
cells from infected mice were treated in vitro with anti-TNF-α antibodies to measure
the amount of IL-17 produced. The following two specific aims were tested: (1)
determine the effect of TNF-α on IL-17 in the immune response to B. burgdorferi
infection and (2) determine the effects of TNF-α on the borreliacidal antibody
response following infection with B. burgdorferi.

During the immune response to B. burgdorferi, macrophages and neutrophils are
activated to produce inflammatory cytokines including IL-1β, TNF-α, and IL-6 that,
in turn, activate an inflammatory cascade with an aim to kill the pathogen. This
interaction further yields production of IL-12 that is necessary for survival of Th1
cells and IL-6 that is needed for Th17 cells. T cells then continue to perpetuate this
positive feedback loop by releasing TNF-α, IL-17, and other cytokines. Research
suggests that IL-17 regulates inflammation by acting on TNF-α (Fossiez et al.,
1996; Jovanovic et al., 1998; Zwerina et al., 2012). While these studies indicate
that IL-17 affects TNF-α production, other research demonstrates that, actually,
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TNF-α mediates IL-17 production (Iwamoto et al., 2007, Chen et al., 2001). What
is known is that both TNF-α (Yssel et al., 1991) and IL-17 (Codolo et al., 2008,
2013) are produced in response to B. burgdorferi infection in humans, and that IL17 contributes to Lyme arthritis development in mice (Burchill et al. 2003; Hansen
et al. 2013). Surprisingly, treatment with anti-TNF-α antibodies to IFN-γ-deficient,
Borrelia-vaccinated

and

-infected

mice

aggravated

arthritis

in

mice

(Christopherson et al., 2003). Therefore, we set out to determine if TNF-α would
have same protective role in a standard infection model of Lyme arthritis and,
importantly, if TNF-α would induce IL-17 production, leading to inflammation.

In this study, we show that TNF-α plays a protective role during inflammation
elicited by B. burgdorferi infection in C57BL/6 mice. Additionally, TNF-α affects IL17 production. These findings were evident when anti-TNF-α antibodies were
injected into B. burgdorferi-infected wild-type mice for four consecutive days, and
the mice presented with increased (although not significant statistically) swelling
of the hind paws compared to untreated control mice (data not shown and Fig. 1).
Furthermore, IL-17 production significantly increased in infected mice when they
were treated with anti-TNF-α antibodies (Fig. 3). Additionally, greater amounts of
IL-17 were measured from spleen cells that were obtained from infected, wild-type
mice and that were treated in vitro with anti-TNF-α antibodies (Fig. 12). Importantly,
compared to anti-TNF-α antibody-treated mice, both paw swelling and IL-17
production were reduced when mice were additionally injected with anti-IL-17
antibodies (Figs. 1 and 3).
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These results that TNF-α protects against inflammation early after infection with B.
burgdorferi support and extend the findings by Christopherson, et al. (2003). These
researchers showed that Borrelia-vaccinated and -infected, IFN-γ-deficient,
C57BL/6 mice treated with anti-TNF-α antibodies had increased paw swelling and
severe arthritis. They also showed that paws from infected mice injected with
recombinant TNF-α displayed decreased swelling and amelioration of arthritis
(Christopherson et al., 2003). It is important to note that they obtained these results
using the Borrelia-vaccination and -challenge model arthritis. In contrast, we used
a standard infection model in C57BL/6 mice, which are well known to be resistant
to developing Lyme arthritis. It is possible that one mechanism for this resistance
is that TNF-α is produced after infection with B. burgdorferi and acts in part to
reduce the IL-17 response. In addition, we saw an even greater effect of anti-TNFα antibody in promoting paw inflammation in IL-10-deficient mice. This is important
because this mouse model has recently been suggested as a good model for the
study of Lyme disease in humans (Sonderegger et al., 2012). Furthermore,
Yrjänainen et al. (2007) demonstrated that treatment of infected mice with antiTNF-α antibodies and ceftriaxone actually increases the number of spirochetes in
tissues. It is reasonable to assume that the increased bacterial load could lead to
increased paw swelling and arthritis development. In addition, although we did not
assess pathology here, the increased paw swelling and IL-17 levels in IL-10deficient mice, compared to wild-type mice, are consistent with moderate-tosevere arthritis (Hansen et al., 2013).

46

What role does TNF-α play during inflammation? The protective role of TNF-α is
not uncommon during infections elicited by pathogens, including B. burgdorferi
(Christopherson et al., 2003), Mycobacterium bovis (Olleros et al., 2002) and
Listeria (Grivennikov et al., 2005). In studies of RA, some patients that receive antiTNF-α therapy actually have increased Th17 cytokines (Chen et al., 2011).
Similarly, certain patients that are treated for RA with TNF-α inhibitors may develop
psoriasis skin lesions (Kary et al., 2006, De Gannes et al., 2007). Ma et al. (2010)
analyzed the mechanism of action in development of psoriasis with treatment of
TNF-α antagonists in an animal model of disease, and found that inhibition of TNFα increased IL-17 and interleukin-22 compared to a control treatment. Therefore,
production of the pro-inflammatory cytokine TNF-α may provide a counter-intuitive
role in diseases such as early Lyme borreliosis. It is possible that early production
of TNF-α acts to limit the growth and spread of B. burgdorferi for a period of time,
with the result being that the IL-17 response does not develop immediately.

However, in contrast, other studies showed a decrease in the amount of IL-17
following inhibition of TNF-α. Moran et al. (2009) reported that treatment with antiTNF-α antibodies significantly decreased production of IL-17 in RA patients
classified as responders to TNF-α therapy. Chen et al. (2011) also reported a
decrease in Th17 cytokines from responders treated with TNF-α inhibitors.
Likewise, administration of etanercept (a soluble TNF-α receptor approved for
treatment of RA) to psoriasis patients decreased the number of Th17 cells (Zaba
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et al., 2007). Furthermore, uveitis treatment with anti-TNF-α antibodies affected
CD4 T cells to significantly decrease IL-17 production (Sugita et al., 2012).
Therefore, the effect of TNF-α on IL-17 production likely varies, depending on the
disease model studied. It is possible that infection-induced disease may cause a
different effect on IL-17 than that which is seen during autoimmune diseases.

The varying effect of TNF-α on IL-17 production can be extended to include
regulatory T (Treg) cells, which are widely known to be related in development to
Th17 cells. While treatment with anti-TNF-α antibody in an animal model of
psoriasis lowered the frequency of Treg cells (Ma et al., 2010) in humans with RA,
it was also shown that treatment with adalimumab (a monoclonal TNF-α antibody
approved for treatment of RA) increased Treg cells by decreasing Th17 cells
through inhibition of IL-6 (McGovern et al., 2012). However, the Treg cell increase
was not observed in patients taking etanercept. The correlation between Treg
populations in adalimumab- and etanercept-treated groups was also assessed in
the risk for development of tuberculosis. Patients treated with adalimumab showed
7-17 times greater risk of developing tuberculosis infection than patients treated
with etanercept, which the authors suggest is possible reactivation of latent
infection (Tubach et al., 2009). Since Lyme disease is caused by a bacterium that
also may cause chronic disease, use of anti-TNF-α antibodies needs to be treated
with caution.
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In our study, eight days after B. burgdorferi-infection, no differences in relative paw
swelling were measured between untreated wild-type mice and mice injected with
anti-IL-17 antibodies for four consecutive days (Fig. 1). These results seem to
suggest that IL-17 is not involved in the immune response during B. burgdorferi
infection, contrary to numerous findings (Burchill et al. 2003; Nardelli, et al. 2004,
2005, 2008; Kotloski et al. 2008; Hansen et al., 2013). After 18 hours of incubation,
there was an unexpected increase in IL-17 production from spleen cells collected
from infected, anti-IL-17 antibody treated mice (Fig. 3). However, as expected, 24
hours after incubation, cells harvested from infected, anti-IL-17 antibody-treated
mice produced significantly less IL-17 than cells from infected, untreated controls
(Figs. 6). In addition, in vitro treatments with anti-IL-17 antibody slightly decreased
IL-17 production by wild-type cells when compared to the amounts of IL-17 from
spleen cells harvested from infected but untreated mice (Figs. 14 and 15). A
possible explanation why we did not see a decrease in paw swelling with anti-IL17 antibody treatment is that we treated mice for four days and assessed swelling
at only two time points, before infection and 8 days after infection. Other studies
treated infected wild-type C57BL/6 mice with anti-IL-17 antibodies for 7 days and
measured paw swelling every other day. For example, in a previous study (Hansen
et al., 2013), treatment with anti-IL-17 antibodies was administered for 7 days.
Statistically less swelling was shown in B. burgdorferi-infected, anti-IL-17 antibodytreated mice than infected, untreated wild-type mice at day 6 after infection.
However, as we show here, this difference was not seen at day 8 (Hansen et al.
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2013). Therefore, it is likely that IL-17 is involved in immune response during B.
burgdorferi infection, even though no significance is demonstrated in this study.

How does IL-17 play a role in joint destruction? Under normal conditions, bone
structure depends on the continuous balance of osteoblasts and osteoclasts for
bone remodeling and resorption. During arthritic conditions, osteoclastogenesis is
increased, while production of osteoblasts is decreased, leading to bone erosion.
IL-17 has been implicated in promoting osteoclastogenesis (Zwerina et al., 2012)
through increased production of IL-1β. Additionally, IL-17 is a powerful inducer of
inflammatory cell migration and invasion of the joint tissue (Hot et al., 2012).
Furthermore, IL-17 acts to stop collagen synthesis of bones and synovial tissue,
along with inhibiting prostaglandin synthesis by cartilage cells (Chaubad et al.,
2001). All of these studies point to the direct involvement of IL-17 in bone
destruction in arthritis. The increase in IL-17 following administration of antibodies
to TNF-α after B. burgdorferi infection provide a possible mechanism for the
protection given by TNF-α. While stimulation of PBMCs from healthy patients with
TNF-α did not stimulate production of IL-17 (Ziolkowska et al., 2000), we found
that generally, anti-TNF-α antibody treatment increases IL-17 production in wildtype mice (Figs. 3, 4, and 12). Overall, the amounts of IL-17 in three different
treatment groups of infected mice were higher for an incubation period of 18 hours
than 24 hours (Figs. 3, 4, 6, and 7). Interestingly, treatment of mice with both antiIL-17 and anti-TNF-α antibodies induced undetectable levels of IL-17 in stimulated
wild-type cells (Fig. 7).
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What contributes to this decrease? Literature suggests that TNF-α and IL-17 can
work synergistically. For instance, addition of both TNF-α and IL-17 increased IL1β and IL-6 (Katz et al., 2001) production. It also has been demonstrated that both
IL-17 (Shalom-Barak et al., 1998) and TNF-α (Englaro et al., 1999) mediate
inflammation through the NF-κB pathway which, in turn, produces more
inflammatory cytokines, including IL-6 and IL-8 (Katz et al., 2001), that form a
positive feedback loop. Similarly, the NF-κB pathway is activated during
osteoclastogenesis and bone resorption (Zwerina et al., 2012). Considering that
Th17 cells produce both IL-17 and TNF-α, with TNF-α possibly causing positive
feedback on Th17 cell production, it seems reasonable that inhibition of both of
them may lower IL-17 levels considerably. It is important to emphasize that our
study included a treatment group with both anti-IL-17 and anti-TNF-α antibodies,
and the expected results were a further decrease in IL-17 than what would be seen
with anti-IL-17 antibody treatment alone. This usually did not occur. This possibly
could be due to an already strong neutralizing effect of the anti-IL-17 antibody. In
support of this, using 2.5 µg of anti-IL-17 antibody has been shown to be effective
in preventing arthritis after infection with B. burgdorferi (Burchill et al. 2003; Nardelli
et al. 2004; Hansen et al. 2013). However, at what stage of disease TNF-α takes
on the protective role in B. burgdorferi infection remains to be determined.

Susceptibility to Lyme arthritis differs by mouse strains. Wild-type C57BL/6 mice
are arthritis-resistant, and C3H/HeJ mice are arthritis-susceptible. However,
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Brown et al. (1999) demonstrated that C57BL/6 mice that are deficient in the antiinflammatory cytokine IL-10 are arthritis-susceptible. This study also showed that
macrophages derived from wild-type C57BL/6 mice produce more IL-10 than do
C3H-derived macrophages in response to B. burgdorferi (Brown et al., 1999).
Furthermore, in vitro stimulation of PMBCs from healthy rhesus monkeys and
humans with B. burgdorferi resulted in production of IL-10 and a decrease in IL-12
(Giambartolomei et al., 1998). The higher production of IL-10 in arthritis-resistant
mice provides a possible mechanism for the bacteria to survive in the host long
enough to cause disease. Our results indicate more ankle swelling in infected, IL10-deficient C57BL/6 mice compared to infected wild-type mice (Figs. 1 and 2).
These results were also reported in a previous study (Hansen et al., 2013) and by
others (Brown et al., 1999; Crandall et al., 2006). It has been shown that reduced
levels of IL-10 substantially contribute to arthritis susceptibility in mice otherwise
known to be arthritis-resistant by increased production of IL-17 (Hansen et al.,
2013).

Overall, in our study, infected IL-10-deficient mice treated in vivo with anti-TNF-α
antibodies produced more IL-17 than untreated wild-type mice when cells were
incubated for 18 hours (Fig. 5). In vitro treatment of spleen cells with 2.5 µg and
10 µg of anti-TNF-α also caused increases in IL-17 production in between IL-10deficient and wild-type mice (Fig. 18 and data not shown). However, these
differences were not seen at concentrations of 5 µg, or in anti-IL-17 or dualantibody treated groups (Fig. 18 and data not shown). It is reassuring that our in
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vitro data shows consistent statistical significances in IL-17 production of IL-10deficient mice between untreated and anti-IL-17 antibody treated groups at all
three concentrations (Figs. 15, 16, and 17). These results support in vivo findings
in a previous study (Hansen et al., 2013) and implicate IL-17 in development of
Lyme arthritis. In another study, bone-marrow derived macrophages cultured with
B. burgdorferi and treated with anti-IL-10 antibodies produced increased levels of
pro-inflammatory cytokines, while addition of recombinant IL-10 decreased IFN-γ,
IL-6 and TNF-α (Gautam et al., 2012). Therefore, it is likely that IL-10 controls
multiple inflammatory pathways implicated in development of Lyme arthritis.

How are IL-10 and TNF-α regulated in Lyme arthritis? Literature suggests that IL10 and TNF-α have an inverse relationship in disease. For example, treatment of
synovial fluid mononuclear cells with anti-IL-10 antibodies increased in vitro
production of TNF-α, while addition of recombinant IL-10 to the cells decreased
the amount of TNF-α (Yin et al., 1997). Additionally, when normal blood was
incubated with B. burgdorferi, production of IL-10 was increased, whereas TNF-α
was decreased (Diterich et al., 2001). Furthermore, addition of recombinant IL-10
to cultures of a human monocytic cell line incubated with spirochetes decreased
production of TNF-α (Murthy et al., 2000). However, treatment of these cells with
anti-IL-10 antibodies did not lower the amount of TNF-α produced (Murthy et al.,
2000). IL-10 is known to down-regulate the NF-κB pathway (Lentsch et al., 1997),
while TNF-α up-regulates the NF-κB pathway (Englaro et al., 1999). Macrophages
stimulated with B. burgdorferi showed an increase in NF-κB after stimulation with

53
B. burgdorferi, but when recombinant IL-10 was added, this response was lowered
(Gautam et al., 2011). These studies indicate that IL-10 can regulate the influence
of TNF-α during B. burgdorferi infection and, possibly, Lyme arthritis. We showed
that in the absence of IL-10, blocking TNF-α, more often than not, had little effect
on the production of IL-17. By contrast, in the presence of IL-10, blocking TNF-α
occasionally increased the production of IL-17. Therefore, IL-10 may regulate the
interaction of TNF-α and IL-17 following B. burgdorferi infection. We also showed
that a lack of IL-10 in B. burgdorferi-infected mice causes an extremely strong IL17 response (Hansen et al., 2013). This may explain why blocking TNF-α in vivo
(Fig. 10 and 11) or in vitro (Fig. 15, 16, and 17) did not consistently result in a
change in IL-17 production by cells of infected, IL-10-deficient mice.

Previously, it was shown that recombinant TNF-α can increase the borreliacidal
antibody response in B. burgdorferi-vaccinated and -infected, IFN-γ-deficient mice
(Christopherson et al., 2003). Furthermore, injection of anti-TNF-α antibodies to
these mice significantly reduced borreliacidal antibody titers (Christopherson et al.,
2003). To determine if TNF-α affected the borreliacidal antibody response in wildtype and IL-10-deficient mice infected with B. burgdorferi, serum from was
collected and analyzed by a borreliacidal antibody assay. Contrary to the results
of Christopherson, et al. (2003), the borreliacidal antibody response in infected
wild-type mice was increased when these mice were treated with anti-TNF-α
antibody. However, this increase was only one-fold different (Fig. 19A), and
therefore was likely not significant. Administration of anti-TNF-α antibodies also
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caused a one-fold increase in the borreliacidal antibody titers observed in infected
wild-type mice treated with anti-IL-17 antibodies (Fig. 19A). These conflicting
results may be due to the disease model used. Borrelia-vaccinated and -infected,
IFN-γ-deficient C57BL/6 mice exhibit severe arthritis, while infected wild-type
C57BL/6 mice exhibit mild inflammation. To support this, we showed that infected
IL-10-deficient C57BL/6 mice (which are moderately-to-severely arthritic) showed
a three-fold decrease in borreliacidal antibody titers (10240 to 1280) due to antiTNF-α antibody treatment (Fig. 19B). These results are similar to those of
Christopherson et al. (2003), which showed decreased borreliacidal titers in mice
infected with B. burgdorferi and treated with anti-TNF-α. Infected IL-10-deficient
mice also showed a five-fold decrease (10240 to 320) due to anti-IL-17 antibody
treatment (Fig. 19B), indicating that TNF-α and IL-17 each promote borreliacidal
activity in IL-10-deficient mice. Additionally, we showed a similar titer for both
infected but untreated wild-type and IL-10-deficient mice (Figs. 19A and 19B).
Contrary to our studies, Brown et al. (1999) showed differences between
borreliacidal titers in wild-type and IL-10-deficient C57BL/6 mice. However, it is
important to note that these borreliacidal antibodies were analyzed four weeks
after infection, while we quantified borreliacidal titers eight days after infection. It is
highly likely that extended infection could alter the borreliacidal response and
magnify differences between the two strains of mice.
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CHAPTER 5: CONCLUSION AND FUTURE DIRECTIONS
In conclusion, this thesis addressed two specific aims. Specific Aim 1 was to
determine the effect of TNF-α on IL-17 in the immune response to B. burgdorferi
infection. The working hypothesis of this specific aim was that TNF-α would
decrease IL-17 production following B. burgdorferi infection. This hypothesis was
partially supported by the data presented in this study. Briefly, it was shown that
anti-TNF-α antibody treatment of B. burgdorferi-infected wild-type mice increased
the IL-17 levels produced by spleen cells. By contrast, this effect was not
consistently observed in IL-10-deficient mice, although we did show that
unstimulated cells from infected, anti-TNF-α antibody-treated mice produced a
relatively large amount of IL-17. Overall, these data indicate that TNF-α may play
a protective role during B. burgdorferi infection in C57BL/6 mice by suppressing
the production of IL-17.

Specific Aim 2 addressed effects of TNF-α and IL-17 on the borreliacidal antibody
response following infection with B. burgdorferi. The working hypothesis for this
aim stated that anti-TNF-α treatment of B. burgdorferi-infected mice would inhibit
borreliacidal antibody production, which would be reversed by also blocking IL-17.
This hypothesis was also partially supported. Our data indicated that in infected
wild-type mice, treatment with anti-TNF-α antibody had a minimal effect on
increasing borreliacidal antibody titers. Additionally treating these mice with antiIL-17 antibodies minimally reduced this production relative to anti-TNF-α antibodytreated mice, but minimally increased production compared to anti-IL-17 antibody-
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treated mice. However, in infected IL-10-deficient mice, treatment with anti-TNF-α
antibodies did, indeed, reduce borreliacidal antibody titers. However, addition
blockage of IL-17 further reduced these titers, rather than reversed the effects of
anti-TNF-α antibody treatment.

These conclusions additionally support the literature that suggests that TNF-α
plays a protective role in B. burgdorferi infection. We provide a potential
mechanism for this protection: inhibiting the production of IL-17, which has been
shown to contribute to the development of Lyme arthritis in mouse models of
disease (Burchill, et al. 2003; Nardelli et al. 2004, 2005, 2008; Hansen et al. 2013).
However, other findings provide a warning about the use of anti-TNF-α therapy in
treating Lyme arthritis because these treatments (1) may stimulate persisting
infection (Yrjänainen et al., 2007), (2) increase IL-17 levels (Chen et al., 2011) in
other systems, and (3) affect production of Treg cells (Ma et al., 2010; McGovern
et al., 2012) which may or may not be desirable in the context of infection-mediated
inflammation.

In conclusion, we show that TNF-α can play a protective role during B. burgdorferi
infection and provide support that this protection involves suppressing IL-17
production. Future studies that require investigation include examining the effect
of IL-17 on TNF-α production during B. burgdorferi infection. Additionally, the
relationship between IL-17 and TNF-α will be studied in the early and later stages
of B. burgdorferi infection, since the effects of TNF-α vary based on the disease
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system, as well as the phase of disease at which it is considered (Grivennikov et
al., 2005).
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